About Pazolab - 40mg Injection
Discover the noble efficacy of Pazolab - 40mg Injection, a famed anti-cancer solution under the therapeutic class of antineoplastic agents. This marvelously crafted intravenous formulation contains Pazopanib Hydrochloride, designed exclusively for adults battling advanced renal cell carcinoma. With regulatory approval from DCGI and marketed by the esteemed Hetero Drugs Limited, Pazolab promises reliability and safety. Take advantage of our sizzling promotion and offer - one clear, colorless vial per box, shelf life of 24 months. Medical supervision is required, ensuring optimal results in this prescription-only tyrosine kinase inhibitor. Originating from India, Pazolab delivers proven benefits to patients worldwide.
Pazolab-40mg: Features & Commercial Advantages
Pazolab-40mg Injection stands out with its clear, colorless liquid form, defined dosage precision, and Marvelous efficacy in treating advanced kidney cancer. The active ingredient, Pazopanib Hydrochloride, delivers targeted anti-cancer effects. Its DCGI-approved profile ensures confidence for traders, suppliers, and exporters across India. The major advantage is its role in improving therapeutic outcomes for adults under medical supervision, making it a preferred choice in oncology commerce.
Packaging, Export, and Supply Details
Quotation for Pazolab-40mg Injection is available for domestic mar and international clients. Each box contains a single vial, transported with care to maintain product integrity-store below 25C and protect from light. Main export markets include Asia, Africa, and beyond, with service providers and traders ensuring swift distribution. Hetero Drugs Limited guarantees robust supply ability to meet global demand through efficient transportation and timely deliveries.
FAQ's of Pazolab - 40mg Injection:
Q: How should Pazolab-40mg Injection be administered?
A: Pazolab-40mg Injection is administered intravenously under strict medical supervision, following dosage guidelines as directed by a physician.
Q: What is the primary benefit of using Pazolab-40mg Injection?
A: The primary benefit of Pazolab-40mg Injection is its targeted treatment of advanced renal cell carcinoma, aiding in effective cancer management for suitable adult patients.
Q: When should patients avoid taking Pazolab-40mg Injection?
A: Patients with known hypersensitivity to Pazopanib should avoid using Pazolab-40mg Injection, as it is contraindicated in such cases.
Q: Where is Pazolab-40mg Injection manufactured and marketed?
A: Pazolab-40mg Injection is manufactured and marketed by Hetero Drugs Limited in India, with regulatory approval from DCGI.
Q: What process is followed for Pazolab-40mg Injection export and supply?
A: Export and supply of Pazolab-40mg Injection involve secure packaging, quotation for domestic and global markets, and careful transportation to ensure product quality upon delivery.
Q: How long is the shelf life of Pazolab-40mg Injection?
A: Pazolab-40mg Injection has a shelf life of 24 months from the date of manufacture when stored as per recommended guidelines.